Posted January 21, 2009
Iconic Therapeutics
Georgia-based Iconic Therapeutics raises $2.57M
Post a comment
Print this storyE-mail story
Share
Iconic Therapeutics
Site Search
ATLANTA, Ga. —
Iconic Therapeutics, a startup focused on a new means of combating cancer and eye disease, has closed on $2.57 million in third-round financing.
VentureWire reported the closing Tuesday. Iconic is seeking to raise $4.2 million.
Icon is in pre-clinical development of technology discovered at Yale University that uses molecules called icon to kill tumors. The icon molecules kill tumors by destroying the blood vessels that feed them.
The company also is combating wet macular degeneration, an eye disease that destroys the vision in older Americans. There are two forms of macular degeneration that destroys the retina – wet, which affects about 10 percent of victims, and dry.
Icon licensed the technology from Yale.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
